Tumor Genomic Profiling denied as duplicate or overlapping therapy by Humana?

Humana's specific coverage criteria for tumor genomic profiling are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied This Tumor Genomic Profiling Test as Duplicate Therapy

Humana may issue a duplicate-therapy denial when its records reflect that a genomic profiling test — or a test it considers clinically equivalent — was already performed and resulted in actionable data within a recent lookback window. The insurer's position is that re-testing provides no additional clinical value when prior results are available and still relevant to treatment decisions.

This denial is often appealable because "duplicate" can be misapplied. Different assays cover different genes, variant classes, or specimen types. A prior test on an earlier tumor specimen may not reflect the current tumor's biology, particularly after disease progression, new metastatic sites, or prior treatment. Your oncologist's clinical judgment that additional profiling is medically necessary — and distinct from prior testing — is central to the appeal.

## Federal Appeal Framework

Under ACA Section 2719, if your plan is non-grandfathered, you are entitled to internal appeal followed by an independent external review. You generally have 180 days from the denial notice to file an internal appeal, and external review typically must be requested within 4 months of exhausting internal options. If your situation is urgent — for example, treatment decisions are time-sensitive — you may qualify for expedited review, which compresses timelines significantly. ERISA-governed employer plans carry the same full-and-fair review requirements under ERISA Section 503.

## Concrete Appeal Steps

1. Request the complete denial letter and the specific clinical policy language Humana applied. 2. Obtain the claims history Humana used to identify the "prior" test — confirm exactly what test it was and what it covered. 3. Have your oncologist document in writing why the new test is clinically distinct and necessary. 4. Submit your internal appeal with supporting records within Humana's stated deadline. 5. If denied again, file for independent external review.

## Documentation to Gather

• Diagnosis confirmation: Pathology report, staging records, and any evidence of disease progression or new biopsy site.
• Prior test records: Report of the earlier test, including which genes/panels were assessed and the date it was performed.
• Clinical distinction letter: A signed letter from your treating oncologist explaining (a) what the prior test did and did not cover, (b) how the tumor's biology or disease state has changed, and (c) why re-profiling or expanded profiling is medically necessary for current treatment decisions.
• Guideline support: Reference the applicable NCCN guideline recommending genomic testing for your specific cancer type and stage — without citing specific numbers, note that your oncologist's assessment confirms you meet the criteria.

## Criteria-Mapping Structure

Copy each requirement from Humana's coverage policy for genomic profiling. For each requirement, note the exact chart fact that satisfies it. For the "duplicate" criterion specifically: document the date, assay name, and gene scope of any prior test versus the scope of the requested test, and have your oncologist attest to the clinical gap.